339941-134x178.jpg

May/June 2017

Volume 18, Issue 3

 

Browse other issues »Subscribe to our print issues »

Articles in this Issue

  • Sourcing Raw Materials for Chemical Manufacturing: Key Tips for Qualifying Suppliers

    Edward S. Price
    As every Contract Manufacturing Organization (CMO) knows, sourcing raw materials is critical to drug development and can make or break the chances for successful commercialization. Whether the project requires off-the-shelf or customized ingredients, cultivating sound, trustworthy and reliable supplier relationships significantly increases the chances of minimizing impurities and meeting project timelines.
  • Contamination Control and Environmental Monitoring Program Results from a GMP QC Cell-Based...

    Peter Wunderli, Ph.D., Jon Denissen, PhD, Maggie Bach, Moira Elmore, PhD, Erica Golueke
    PPD’s QC bioassay laboratories in Middleton, Wisconsin, U.S., and Athlone, Ireland, previously reported observations regarding contamination control (CC) and environmental monitoring (EM) made over time and across program changes (Pharmaceutical Outsourcing, March/April 2016).
  • Phase-Appropriate Frameworks at the Intersection of CMC and cGMP Pathways

    Mihaela Simianu
    Pressure and scrutiny from regulators, customers, and stakeholders continue to drive the pharmaceutical industry to search for alternate ways to produce quality medicines at reasonable cost.
  • Optimizing an Electronic SAE Workflow in a Cloud-Based Safety Database

    Sharon Wyatt Moore, MD, MBA, MPH, Andrew Kilpatrick, PhD
    Pharmaceutical drug development occurs in one of the most dynamic environments - an environment that is always seeking new and innovative methods to increase efficiency and reduce timelines while improving patient safety, ensuring data integrity and complying with all regulatory requirements.
  • Oral Solid Dosage Manufacturing Roundtable

    What are some of the current critical issues facing the industry in regards to oral solid dosage manufacturing?
  • Ensuring Effective Drug Stability Studies

    Dr. Hildegard Bruemmer
    Stability testing demonstrates how the quality of a drug substance or drug product may be influenced by temperature, light, humidity and other environmental factors, and is used to show shelf life within recommended storage conditions. Studies to evaluate any physical, chemical, biological, and microbiological attributes that may change during storage can be complex and costly.
  • Trends in Biopharma Contract Manufacturing in China and India

    Vicky Qing Xia, Ronald A. Rader
    Recent growth in the biopharmaceutical industry in both China, and India suggest a future positive outlook for contract manufacturing in both regions.
  • The Next Great Serial: Pharmaceutical Security

    Nigel Walker
    A patient recently diagnosed with a chronic illness is prescribed a medication. The physician trusts this drug and, as a result, the patient assumes that it will help him/her manage the condition. Though neither party may give much thought to how the medication was produced or how it made its way to the pharmacy, odds are it changed hands several times. How can the patient be sure the medication he/she is going to take is exactly what the doctor ordered?
  • Future of Pharmaceutical, Biotech and Device Development and Manufacturing Innovation Showcased...

    International Pharmaceutical Expo (INTERPHEX), the premier event dedicated to pharmaceutical and biotechnology innovation, technology and knowledge from development through commercialization, and sponsored by the Parenteral Drug Association (PDA), today announced once again INTERPHEX has proven to be the place to “Learn It, Experience It, Procure It” aggregating more than 7400 key decision makers sourcing solutions. This year’s exhibit hall featured 635 leading suppliers, a cuttingedge, no-cost technical conference, a two-day keynote series, a three-day INTERPHEX Live program, and an Exhibitor Awards program.
  • HORIZON LINES: A Quarterly Review of NDAs Sept-Oct 2016

    Harshada Sant, MS, Amitkumar Lad, PhD, Hemant N. Joshi, Ph.D., MBA
    This column summarizes New Drug Applications (NDAs) approved in the September-October 2016 timeframe. FDA approved 20 NDAs in these two months.
  • <<
  • >>